STAT3与VEGF在喉癌中的研究进展.

[4]Zisman A,Pantuck AJ,Dorey F,et al.Improved prognostication of r enal cell carcinoma using an integrated sta ging system[J].J C lin Oncol,2001,19(6:1649-1657.

[5]M otzer RJ,Hutson TE,Tomcza k P,et al.S unitinib versus inter feron alfa in metastatic renal-cell car cinoma[J].N Engl J Med,2007, 356(2:115-124.

[6]S ternber g CN,Davis ID,Ma rdia k J,et al.Pazopanib in locally ad- va nced or metastatic renal cell car cinoma:results of a random ized phaseⅢtrial[J].J Clin Oncol,2010,28(6:1061-1068.

[7]Hudes G,Car ducci M,Tomczak P,et al.Temsir olimus,inter feron alfa,or both for a dvanced renal-cell car cinom a[J].N Engl J Med, 2007,356(22:2271-2281.

[8]M otzer RJ,Escudier B,Oudar d S,et al.Effica cy of ever olimus in ad- v anced rena l cell car cinoma:a double-blind,randomised,placebo-

contr olled phaseⅢtr ial[J].Lancet,2008,372(9637:449-456. [9]Robson CJ,Churchill B M,Ander son W.The results of radical ne-

phr ectomy for r enal cell carcinoma[J].J Urol,1969,101(3:297- 301.

[10]Patar d J J,S hva rts O,Lam J S,et al.S afety and efficacy of pa rtial

nephrectom y for all T1tumors based on a n inter national multicenter experience[J].J Urol,2004,171(6Pt1:2181-2185.

[11]B aillargeon-GagnéS,J eldr es C,Lughezzani G,et al.A compar ative population-ba sed analysis of the rate of par tial vs radical nephr ecto- my for clinically localized r enal cell car cinom a[J].BJ U Int,2010, 105(3:359-364.

[12]C owey CL,Amin C,Pruthi RS,et al.Neoadjuvant clinical tr ial w ith sor afenib for patients with sta geⅡor higher renal cell ca rcinoma [J].J Clin Oncol,2010,28(9:1502-1507.

[13]va n der Veldt AA,Meijer ink MR,van den Eertw egh AJ,et al. S unitinib for tr eatment of advanced renal cell ca ncer:pr im ary tumor r esponse[J].Clin Cancer Res,2008,14(8:2431-2436.

[14]J onasch E,Wood CG,M atin S F,et al.PhaseⅡpr esurgical feasi- bility study of bev acizumab in untr eated patients with metastatic re- nal cell ca rcinoma[J].J Clin Oncol,2009,27(25:4076-4081. [15]Stephenson AJ,Chetner MP,Rourke K,et al.Guidelines for the

surveillance of loca lized renal cell ca rcinoma based on the pa tterns of relapse after nephrectomy[J].J Urol,2004,172(1:58-62. [16]Escudier B,Kor alewski P,Pluzanska A,et al.Bevacizumab plus in-

terfer on alfa-2a for treatment of metastatic renal cell carcinoma:a randomised,double-blind phaseⅢtrial[J].La ncet,2007,370: 2103-2111.

[17]Plim ack E R,Tannir N,Lin E,et al.Patterns of disease prog ression in metastatic renal cell car cinoma pa tients treated with antivascular agents and inter feron:impa ct of ther apy on recurr ence patter ns and outcome measur es[J].Cancer,2009,115(9:1859-1866.

[18]Nguyen DX,Bos PD,MassaguéJ.Metastasis:fr om dissemina- tion to organ-specific c olonization[J].Nat Rev Cancer,2009,9 (4:274-284.

[19]Mancuso M R,Dav is R,Norber g S M,et al.Rapid vascular reg row th in tum ors after r eversal of VEGF inhibition[J].J Clin Invest,2006, 116(10:2610-2621.

[20]Casanovas O,H icklin DJ,Ber gers G,et al.Dr ug resistance by eva- sion of antia ngiogenic targ eting of VEGF signa ling in late-stage

pancreatic islet tumors[J].Cancer C ell,2005,8(4:299-309. [21]Huang D,Ding Y,Li Y,et al.Sunitinib acts prima rily on tumor en-

dothelium ra ther than tumor cells to inhibit the growth of renal cell carcinoma[J].Cancer Res,2010,70(3:1053-1062.

[22]Ebos J M,Lee CR,Cruz-M unoz W,et al.Accelerated metastasis af- ter shor t-term tr eatment with a potent inhibitor of tumor angiog ene- sis[J].Ca ncer Cell,2009,15(3:232-239.

[23]Pàez-Ribes M,Allen E,Hudock J,et al.Antia ngiogenic ther apy e- licits malignant pr ogression of tumor s to increa sed local invasion and distant meta stasis[J].Cancer C ell,2009,15(3:220-231. 收稿日期:2011-09-26 修回日期:2011-12-27 编辑:潘雪 S TAT3与VEGF在喉癌中的研究进展 李楠1△(综述,杨小敏2※(审校

(1.广东医学院,广东湛江524023; 2.惠州市中心人民医院耳鼻咽喉科,广东惠州516001

中图分类号:R739.65 文献标识码:A 文章编号:1006-2084(201209-1319-04 摘要:喉癌的发生、发展受多种基因的调控,信号转导及转录活化因子3(STAT3和血管内皮生长因子(VEGF在喉癌的发生、发展、转移及预后中起重要作用。S TAT3由细胞外细胞因子、生长因子等多肽类配体激活,作用于细胞核内特异的DNA片段,调控靶基因的转录,促进细胞的增殖、抑制凋亡。肿瘤的生长依赖肿瘤新生血管的形成,VEGF是重要的血管生成正性调节因子,所以对STAT3和VEGF的一些相关性研究为喉癌发生、发展机制的阐述奠定了基础。

关键词:信号转导及转录活化因子3;血管内皮生长因子;喉癌

Research Pro gre ss o f STAT3and VEG F in L aryngeal Cancer LI Nan1,YANG Xiao-min2.(1.Guang-dong Medical College,Zhanjiang524023,China;2.Dep artment of Otorhinolaryngology,H uiz hou Centr al People′s H ospital,H uizhou516001,China

Abst rac t:The occurrence and progress of lar yng eal neoplasm s ar e r egula ted by many genes,signal tr ans-ducers and activa tors of transcription3(S TAT3and VEGF play s important roles in the occurr ence,prog ress, m etastasis and prognosis of laryngeal neoplasms.STAT3is activated by extr acellular lig ands,including cyto-kines a nd g rowth factors.It can translocate to nucleus,w her e it binds to specific DNA sequences and regu-lates the tra nscription of tar get genes,and promotes the prolifera tion and inhibits a poptosis of tumor cells.

Tumor g rowth relies on angiogenesis,VEGF pla ys an important role in angiog enesis a s a positive r egulatory fa ctor.S o some studies a bout the S TAT3and VEGF a re carr ied out to establish foundation for genesis mecha-nism of human la ryngeal cancer.

Key words:Signal tr ansducer s and activator s of transcr iption3;Va sculal endothelial grow th fa ctor;La-ryngeal cancer

喉癌是头颈部常见恶性肿瘤,占全身恶性肿瘤 的5.7%~7.6%[1],主要病理类型为鳞状细胞癌。其

发病的病因尚不十分清楚,其发生、发展及转移过程中相关蛋白质的过度表达或异常激活是目前的研究热点。信号转导及转录活化因子(signa l tra nsducer s a nd a ct i-vat or s of t ra nscr iption,S TAT s是一种存在于细胞质并在激活后能够转入核内与DNA 结合的独特的蛋白家族,它与酪氨酸磷酸化信号通道耦联,发挥信号转导和转录调控的作用。其中,S TAT3是家族中的重要一员,在很多不同类型的细胞和组织中均有S TAT3表达,其参与细胞